All PlansPrior AuthMedium impact
Secukinumab (Cosentyx®)
BCBS Tennessee·TN · Rheumatology, Dermatology·Medical Policy
Effective date
Sep 1, 2026
We identified it
Jun 17, 2026
Summary
New prior authorization policy for Cosentyx (secukinumab) will require step therapy and specialist prescribing for multiple conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis. Policy includes detailed coverage criteria and documentation requirements for each indication.
Action Required
Before September 1, 2026: Update prior authorization workflows for Cosentyx prescriptions. Ensure rheumatologists and dermatologists are aware of new step therapy requirements and documentation criteria. Train billing staff on condition-specific coverage requirements and continuation therapy documentation needs. Review step therapy guide at provided URL for complete requirements.